FDA Panel Backs Compounding of Peptide BPC-157, Hims & Hers Shares Jump 8%
HIMS has more than doubled off its 52-week low of $13.74.
Summary
An FDA advisory panel voted 8-6-1 to recommend allowing pharmacies to compound BPC-157, the first of seven peptides under review for looser compounding rules. The vote is a regulatory green light for the telehealth industry, with analysts estimating the peptide market could reach $2-3 billion if legitimized. Hims & Hers, which spoke in favor of peptides at the meeting, saw its stock rise 8% as the outcome signals support for its plans to offer compounded peptide products. This follows the company's recent acquisition of Eucalyptus and a $402.5 million convertible note offering, positioning it to capitalize on expanded compounding access. The FDA staff had previously advised against broader compounding, citing safety concerns, making the panel's recommendation a notable shift. Final FDA action is pending, but the vote reduces regulatory uncertainty for Hims & Hers' peptide strategy.
At the time of this announcement, HIMS was trading at $33.48 on NYSE in the Life Sciences sector, with a market capitalization of approximately $7.7B. The 52-week trading range was $13.74 to $70.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.